help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 1, 9-20, January 2006; doi:10.1634/theoncologist.11-1-9
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benjamin, R. S.
Right arrow Articles by Eisenberg, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benjamin, R. S.
Right arrow Articles by Eisenberg, B.

Management of Gastrointestinal Stromal Tumors in the Imatinib Era: Selected Case Studies

Robert S. Benjamina, Charles D. Blankeb, Jean-Yves Blayc, Sylvie Bonvalotd, Burton Eisenberge

a University of Texas MD Anderson Cancer Center, Houston, Texas, USA; b Oregon Health & Science University, Portland, Oregon, USA; c Hôpital Edouard Herriot and Centre Léon Bérard, Lyons, France; d Institut Gustave Roussy, Paris, France; e Norris Cotton Cancer Center, Lebanon, New Hampshire, USA

Key Words. Gastrointestinal stromal tumor therapy • GIST • KIT • CD117 • Tyrosine-kinase inhibition • Imatinib

Correspondence: Robert S. Benjamin, M.D., Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard. Box 0450, Houston, Texas, 77030, USA. Telephone: 713-792-3626; Fax: 713-794-1934; e-mail: rbenjami{at}mdanderson.org

The introduction of imatinib, an orally administered inhibitor of the KIT receptor tyrosine kinase, is prompting revision of the management algorithms that have traditionally guided the treatment of gastrointestinal stromal tumor (GIST). Historically, patients with GISTs have had substantial rates of relapse as well as limited long-term survival even after complete surgical resection of a primary tumor. Imatinib has been shown to induce durable tumor responses in more than half of the patients with malignant metastatic or unresectable GISTs and to halt disease progression in an additional third. These encouraging results have led to the initiation of clinical trials of imatinib as an adjuvant or neoadjuvant therapy with surgery. Until relevant data are reported to provide definitive direction for the management of operable or potentially operable GISTs, treatment decisions must be made on the basis of the available evidence and clinical experience with imatinib. This paper presents selected case studies describing approaches to the combined use of surgery and systemic therapy that have been applied in the treatment of individual GIST patients. The management of GIST in these cases required a coordinated, multidisciplinary approach involving medical oncologists, diagnostic radiologists, gastroenterologists, surgeons, and pathologists.




This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
S. Bonvalot, H. Eldweny, C. Le Pechoux, D. Vanel, P. Terrier, A. Cavalcanti, C. Robert, N. Lassau, and A. Le Cesne
Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era
Ann. Surg. Oncol., December 1, 2006; 13(12): 1596 - 1603.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2006 by AlphaMed Press.